GI CONNECT Update from ASCO GI 2020: cancers of the liver, small intestine and pancreas tract

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

GI CONNECT Update from ASCO GI 2020: cancers of the liver, small intestine and pancreas tract

Assoc. Prof. Yu Sunakawa

GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Yu Sunakawa (Japan) provides the highlights on cancer of the liver, small intestine and pancreas tract.

Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

Biography Disclosures

Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

Dr Yu Sunakawa is a medical oncologist at St. Marianna University, Japan and previously worked as an instructor at Showa University Northern Yokohama Hospital in Yokohama, Japan. He also completed postdoctoral research fellowship training at University of Southern California/Norris Comprehensive Cancer Center in United States. In 2011, Dr Sunakawa received the board certification of the Japanese Society of Medical Oncology. Dr Sunakawa’s research interests are the identification and determination of molecular markers in cancerous tissues or blood that could predict cancer risk and clinical outcome in gastrointestinal cancer. He is also focusing on research regarding tumour immunity and received a Merit Award from the American Society of Clinical Oncology in 2014, for the research of genetic variations in immune checkpoint-related genes.

Assoc. Prof. Yu Sunakawa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Bristol-Myers, Biopharma, Chugai Pharm, Daiichi-Sankyo, Gurdant, Lilly, Ono Pharm, Sanofi, Sysmex, Takeda and Tahio Pharm.

time | open 5 min | Jan 2020

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download slides PDF

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

2 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

5 min

Surveillance and Diagnosis of HCC in Asia: Poster Presentation at...

Sep 2023

Assoc. Prof. Gerald Prager

Video

4 min

Long-term Response in Advanced Colorectal Cancer

Sep 2023

Prof. Dr Jeroen Dekervel

Dr Amit Singal

Podcast

29 min

A New Era in Treating Patients with Advanced HCC

Sep 2023

Dr Jaume Capdevila

Asst. Prof. Mauro Cives

Micro learning

30 min

Accreditation: EACCME

Recognising, Diagnosing and Managing Neuroendocrine Tumours

Aug 2023

Acromegaly and Neuroendocrine Tumours Global Survey

Publication

15 min

Acromegaly and Neuroendocrine Tumours Global Survey

Aug 2023

Prof. Shaheenah Dawood

Assoc. Clinical Professor Rena Callahan

Podcast

74 min

Oral SERDs in ER+ Breast Cancer

Aug 2023

Dr Tracy L Stockley

Prof. David Hong

Podcast

24 min

An Introduction to Molecular Testing

Jul 2023

Dr Neal Shore

Dr Andrew J. Armstrong

Video

10 min

Clinical Implementation of Testing and PARPi as Monotherapy or in...

Aug 2023

Janet Forgenie

Video

3 min

Nursing Support for mCRPC Patients During Radiopharmaceutical Tre...

Jul 2023

Prof. Andrea Sartore-Bianchi

Video

5 min

Conference Update: ASCO and WCGIC 2023

Jul 2023

Other programmes developed by Assoc. Prof. Yu Sunakawa

Assoc. Prof. Yu Sunakawa

Medical Oncologist

St Marianna University

Japan

Review paper on intermittent vs continuous treatment in the maintenance treatment setting of metastatic colorectal cancer

Prof. Tanios Bekaii-Saab

Assoc. Prof. Yu Sunakawa

Prof. Sebastian Stintzing

0 min

Review paper on intermittent vs continuous treatment in the maint...

2016

Assoc. Prof. Joleen Hubbard

Assoc. Prof. Yu Sunakawa

5 min

Which targeted drug (bevacizumab, ramucirumab, aflibercept, or an...

2017

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.